Latest Pharmaceutical News
Innate Immune Grants Cephalon Australia License To Develop Antibodies For Asthma, SLE
Innate Immune, a privately held biotechnology company, has granted Cephalon Australia an exclusive license to develop antibodies for the treatment of asthma and systemic lupus erythematosis (SLE). Cephalon Australia is a wholly owned subsidiary of Cephalon Inc.
Published: 16-Mar-2010
Vertellus Specialties To Expand Vitride Manufacturing Capacity In Michigan
Vertellus Specialties, a specialty chemicals company, is planning to expand its manufacturing capacity of Vitride reducing agent in response to growing worldwide demand.
Published: 16-Mar-2010
Savient Pharma Refiles Biologics License Application For Krystexxa
Savient Pharma has resubmitted its biologics license application (BLA) to FDA for Krystexxa (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy.
Published: 16-Mar-2010
Eli Lilly To Acquire Worldwode License For Acrux Testosterone Solution Axiron
Eli Lilly and Acrux have entered into an exclusive worldwide license agreement for the potential commercialisation of Acrux's experimental underarm testosterone solution (proposed tradename Axiron).
Published: 16-Mar-2010
Hitachi, NextDocs Form Document Management Solutions Partnership For Pharma Manufacturers
Hitachi and NextDocs have formed partnership in document management solutions for pharma manufacturers. Both the parties are expected to provide NextDocs Document Management System to the life sciences companies in Japan.
Published: 16-Mar-2010
Icagen Releases Positive Results Of Phase IIa ICA-105665 Trial
Icagen has reported positive results of its Phase IIa epilepsy study of ICA-105665, an orally available small molecule KCNQ potassium channel agonist.
Published: 16-Mar-2010
Boston Scientific Horizons AMI Trial Compares Taxus Express Stents VS Bare-Metal Stents
Boston Scientific has reported results from an analysis of one-year subset data from the Horizons AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the Taxus Express2 Paclitaxel-Eluting Stent System or the Express bare-metal stent.
Published: 16-Mar-2010
LLS, Forma Join To Develop Anti-cancer Therapies
Leukemia & Lymphoma Society (LLS) and Forma Therapeutics have entered into a partnership to discover and develop novel therapies for cancer patients with diffuse large B cell lymphoma. The companies aim to develop small molecule compounds against the key lymphoma target, Bcl-6.
Published: 15-Mar-2010
Portola Pharma, Merck Say Betrixaban Reduces Bleeding In Patients With Atrial Fibrillation
Portola Pharma and Merck have said that a mid-stage clinical trial of heart drug candidate betrixaban, an investigational oral direct Factor Xa inhibitor, showed reduced instances of bleeding in certain patients.
Published: 15-Mar-2010
Perrigo Begins Shipping Of Zaditor's Generic Version
Perrigo, a global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products, has begun shipping Ketotifen Fumarate ophthalmic solution, 0.025%, a generic version of Zaditor.
Published: 15-Mar-2010
